Acute GVHD (aGVHD) is a major cause of morbidity and mortality after unrelated BMT (UBMT). Our purpose was to analyze the role of extracorporeal photochemotherapy (ECP) in controlling grade II-IV aGVHD in children given UBMT. Of 41 consecutive children, 31 developed grade II-IV aGVHD after UBMT: 16 had a good response to steroids (GR group), whereas 15 underwent ECP (ECP group) within 100 days of UBMT. Eligibility criteria for starting ECP were steroid resistance, dependence or viral reactivations. Criteria for judging response to aGVHD treatment were that the resolution of all signs were considered a complete response (CR), at least a 50% improvement was classified as a partial response (PR) and stable or progressive disease was judged as no response (NR). On completing ECP, the CR rate was 73%, whereas the GR group had a CR rate of 56% by day 100. The 2-year overall survival and progression-free survival rates were 57 and 67% in the GR group vs 85 and 87% in the ECP group. Our data seem to suggest that ECP may improve outcome in patients after UBMT. These findings need to be confirmed in a larger population.
Introduction
The recognition of alloantigen by T cells in the graft paves the way to acute GVHD (aGVHD). 1, 2 The clinical factors capable of influencing the onset of GVHD relate to donorhost factors, the source of stem cells and preparatory regimens administered prior to the transplant. Among the donor-host variables, the most commonly recognized GVHD risk factors are HLA differences, female donor to male recipient combinations, donor and recipient ages. Unfortunately, finding a matched related donor is becoming increasingly difficult in Italy, whereas the use of alternative donors or mismatched relatives is increasing.
Administering antithymocyte globulin (ATG) or Campath-1H together with the conditioning regimen succeeds in reducing the incidence of aGVHD, 3 but this condition nonetheless remains the major cause of morbidity and mortality after unrelated BMT (UBMT). 4 Although it is generally agreed that steroids are the first-line therapy for aGVHD, there is little consensus as to the best approach to steroid-refractory GVHD. Extracorporeal photochemotherapy (ECP) has recently attracted attention because of its potential capacity to limit the ongoing process of GVHD without inducing further immune suppression. 5, 6 The aim of the present study was to analyze the role of ECP in controlling aGVHD grades II-IV in children. At our center, the eligibility criteria for ECP were steroid resistance or dependence, or viral reactivations. The transplant-related mortality (TRM), overall survival (OS), progression-free survival (PFS) and event-free survival (EFS) of patients treated with ECP were compared with cases not eligible for ECP and responding well to steroids.
Patients and methods
The study considered 41 consecutive children transplanted at the SCT Unit of the Pediatric Onco-Hematology Clinic of the University of Padova between December 1999 and April 2005, who had a follow-up of at least 1 year after UBMT. The children suffered from AML or ALL or nonHodgkin lymphoma (NHL), and were given a myeloablative conditioning regimen. All patients received fluconazole as of day À7, and high-dose immunoglobulin (400 mg/kg) every 3 weeks from day À7 to day þ 100 for prophylaxis against infection. To prevent CMV and herpes virus reactivation, acyclovir was administered i.v. from day À7 to day þ 30 (500 mg/m 2 every 8 h), then orally for 6 months after the transplant. Oral cotrimoxazole was administered, starting on day þ 30 and continuing till the end of the immunosuppressive treatment, for prophylaxis against Pneumocystis carinii pneumonia. Viral reactivations were detected by PCR positivity for EBV-DNA (cutoff: 300 copies) and CMV-DNA (cutoff: 300 copies). Patients experiencing CMV reactivation were usually treated with ganciclovir or foscarnet. Cyclosporine A was given at 3 mg/kg/d i.v. from d À1 lo d +30, then orally at 6 mg/kg for 12 months, together with 3.75 mg/kg rabbit antithymocyte globulin (ATG) from days À3 to À1 and short-term methotrexate were administered for GVHD prophylaxis. Of the 41 patients, 10 did not develop aGVHD or had mild form (grade I) and were excluded from the analysis. All patients with aGVHD grades II-IV received 2 mg/kg per day of methylprednisolone (MPred) as first-line therapy. Steroid refractory GVHD was defined as a progression or no improvement in aGVHD after at least 4 days on MPred X2 mg/kg body weight; steroid-dependent GVHD was defined as a flare-up of aGVHD during the tapering of MPred. 2 The criteria for starting ECP to treat viral reactivations were as follows: an increasing EBV viral load even after reducing immunosuppression (IS) therapy to 50% or the occurrence of X2 episodes of CMV reactivation.
Among the 31 children who developed grade II-IV aGVHD, 16 were patients with good response to steroids (GR group) whereas 15 were eligible for ECP within 100 days of UBMT due to steroid resistance after treatment for 4-8 days (7 patients), steroid dependence (4 patients), viral reactivations (4 patients). The median time elapsing between the transplant and starting ECP was 43 days (range 13-85).
The two groups of children (GR vs ECP) were comparable in terms of recipient/donor sex matching, disease, conditioning regimen, immunological status before UBMT and recipient/donor CMV status matching.
Of the patients, 18 were male and 13 were female; their median age at transplantation was 11.5 years (range 1.4-18.3); their primary diseases were ALL in 19 cases, AML in 9 and NHL in 3; Table 1 shows the patients' characteristics.
Informed consent was obtained from patients or their parents, as applicable, before implementing ECP.
Clinical assessment
The clinical stage of organ involvement was graded and then combined to obtain an overall grade, in accordance with published criteria, for aGVHD or chronic GVHD (cGVHD). [7] [8] [9] [10] The diagnosis of GVHD was confirmed by histology whenever clinically indicated. aGVHD In the GR group, the overall clinical grades of aGVHD were grade II in 13 cases, grade III in 1 and grade IV in 2. Among the 16 patients, the skin was involved in 13, the liver in 3 and the gastrointestinal (GI) tract in 14. In particular, five children had only one organ involved (the skin or GI tract), eight had two organs involved (the skin and GI tract) and three had three organs involved (the skin, liver and GI tract).
In the ECP group, the overall clinical grade of aGVHD was grade II in 7 cases, grade III in 4, and grade IV in 4; the skin was affected in 13 of the 15 cases, the GI tract in 14 and the liver in 1. Three patients had only one organ involved (the skin or GI tract), eleven had two (the skin and GI tract) and one patient had three (the skin, liver and GI tract). Table 2 summarizes the overall clinical grades of aGVHD and the organs involved. The median Lansky/ Karnofsky performance score at the start of ECP was 60% (range 30-90).
Photopheresis procedure ECP was performed as follows: a Spectra Cobe cell separator (Lakewood, CO, USA; release 4.6 and 6.0) was used to process 2 vol of the patient's blood. The maximum final volume of mononuclear cells (MNC) to collect was set at 150 ml, with a hematocrit below 3%. The MNC collected were adjusted to a constant volume of 300 ml by adding normal saline and 3 ml of 8 MOP (measure of performance) to obtain a final concentration of 200 mg/ml. The buffy coat thus diluted was transferred into a special UVA-permeable bag (Maco Pharma, Tourcoing, France), and UVA irradiation was performed with a Puva Combi Light (Italy) at 2 J/cm 2 . The 8-MOP photo-activated product was then reinfused into the patient within 30 min. In children with a body weight below 15 kg, the Hb level was maintained above 12 g per 100 ml. For this purpose, a filtered and irradiated red blood cell unit was available for line filling before starting the procedure. The average duration of the procedure was 180-240 min. During ECP, patients were monitored for blood pressure, heart rate and body temperature. Full blood cell counts, liver and kidney function tests, and coagulation parameters were obtained before each procedure. All adverse effects observed during the procedures were recorded. None of the patients required sedation during the procedure.
Treatment protocol
As a rule, patients were treated with ECP on 2 consecutive days at 1-week intervals for the first month, then every 2 weeks during the second and third months and then monthly for at least another 3 months (6 months of treatment in all). Any concomitant immunosuppressive therapy was initially maintained, then modified or discontinued, depending on the clinical response.
GVHD response criteria
Complete response (CR) was defined as the resolution of all signs of aGVHD, partial response (PR) as at least a 50% improvement in the clinical signs. In the latter case, given the complexity of assessing response, we defined PR for each organ as follows: for the skin, at least a 50% reduction in the body surface area affected; for the GI tract and liver, a 50% reduction in the volume of diarrhea, bilirubin or alkaline phosphatase. Patients with stable or progressive disease were considered as nonresponders (NR). 11, 12 Viral reactivations were detected by PCR positivity for EBV-DNA (cutoff: 300 copies) and CMV-DNA (cutoff: 300 copies). Patients underwent clinical assessment at the baseline and after 3, 6, 12, 18 and 24 months.
Statistical analysis
Patients' characteristics were compared using the w 2 -test or the Fisher's exact test (as appropriate) in the case of discrete variables, or the Mann-Whitney test in the case of continuous variables. TRM rates at 100 and 180 days were calculated as of the date of UBMT, considering any cause of death other than recurrence of the child's primary disease. OS was calculated as of the date of UBMT up until death due to any cause (including recurrences), or up until the date of the latest follow-up. PFS was calculated from the date of UBMT to the date of recurrence, or the latest follow-up. EFS was calculated from the date of UBMT until recurrences, second malignancies, death due to any cause or up until the date of the latest follow-up. Survival was analyzed using the Kaplan-Meier method with 95% confidence intervals.
Differences between patients with and without ECP were compared using the log-rank test. All reported P-values were two-sided, and statistical significance was set at a ¼ 0.05 (SAS Institute, Cary, NC, USA; release 8.2). 13 
Results

Infections
In the GR group, 3 of 16 children had sepsis within 6 months of the transplant, involving Staphylococcus epidermidis (one case), Staphylococcus cohnni (one case) and Staphylococcus haemolyticus (one case).
In the ECP group, 4 of 15 children developed septic episodes. Among the steroid-resistant patients, these involved S. epidermidis (two cases), before starting ECP; Streptococcus mitis (one case) while on ECP; Pseudomonas (one case) after stopping ECP; in the subgroup with viral reactivation, one patient had Corynebacterium sepsis before the ECP procedure.
Mycosis
No cases of mycosis were recorded in the GR group, whereas one steroid-resistant girl in the ECP group had aspergillosis in the cricoid cartilage after completing the ECP treatment, from which she recovered completely.
CMV reactivation
In the GR group, 11 episodes of CMV reactivation occurred in 8 of 16 patients within 100 days of UBMT, and another 5 episodes were recorded between the third and twelfth months.
In the ECP group, two patients started the procedure for X2 CMV reactivations; three children (two of them steroid resistant and one steroid dependent) had CMV reactivation before starting ECP and one (who was steroid resistant) within the first month of ECP.
EBV reactivations
In the GR group, 10 of 16 patients suffered an EBV reactivation; they recovered when their IS therapy was reduced. In the ECP group, EBV reactivation occurred in 6 of 15 patients before starting ECP: 4 of them (2 steroid resistant and 2 steroid dependent) recovered when their IS treatment was reduced, whereas 2 started ECP due to an increasing EBV viral load despite a reduction in their IS therapy. All patients became negative without any deterioration in GVHD symptoms and they were not given additional therapy with rituximab for EBV reactivation.
Acute GVHD response
In the GR group, GVHD disappeared completely by day 100 in 9 of 16 (56%) patients; these included 8 patients with an overall aGVHD grade II, and 1 with an overall grade III. The remaining five patients (44%) achieved a PR, and only two children had persistent cGVHD a year after UBMT.
In detail, a CR was recorded in 46% of patients with skin involvement, 57% of those with gut involvement and 67% of children whose liver was involved.
In the ECP group, after completing the treatment, a CR was recorded in all seven patients with an overall aGVHD grade II, in one of three patients with grade III and in three of five with grade IV. The median time on treatment was 171 days (range 35-311). In short, we recorded 73% of cases achieving a CR and 27% a PR. Signs of aGVHD affecting the skin, gut and liver disappeared in 92, 71 and 100% of patients, respectively. As for the IS therapy, the four steroid-dependent patients discontinued MPred after four ECP cycles. By the end of the ECP, 10 of 15 (67%) patients had discontinued IS therapy. The side effects observed during ECP were generally mild and mainly in children with a low body weight. In detail, these included 15 episodes of mild hypotension and abdominal pain recorded in eight patients; one patient in this group had cGVHD a year after UBMT (and 2 months after stopping ECP).
TRM, causes of death, OS, PFS and EFS
The TRM rate was 6% (CI 0-18) in the GR group and 0% in the ECP group at day 100, with no further increase by day 180.
In the GR group, 1 of 16 patients died of aGVHD, whereas 5 died of recurrent diseases. In the ECP group, 2 of 15 patients died of recurrent diseases.
Patients in the GR group had a 2-year OS rate of 57% (CI 30-84), as opposed to 85% in the ECP group (CI 62-100), P ¼ 0.2. The 2-year PFS rate was 67% (CI 43-91) in the GR group vs 87% (CI 70-100) in the ECP group, P ¼ 0.4. The 2-year EFS rate was 63% (CI 39-86) in the GR series and 87% (CI 69-100) in the ECP group, P ¼ 0.3, (Figure 1) .
No association emerged between age and OS (P ¼ 0.6) or PFS (P ¼ 0.9).
Discussion
The aim of this study was to analyze the role of ECP in controlling grade II-IV aGVHD in 15 children who consecutively underwent UBMT from December 1999 to April 2005. They received ECP for steroid resistance or dependence, rising EBV viral loads despite reducing IS therapy by 50%, or X2 episodes of CMV reactivation. This group was compared with patients transplanted during the same time frame but not eligible for ECP (GR group, 16 patients).
Several parameters were analyzed, for example, incidence of infections, viral reactivations, recovery from aGVHD, TRM, OS, PFS and EFS. Infections are one of the major causes of mortality, morbidity and hospitalization in the first 180 days after UBMT transplantation. In spite of a reportedly low number of leukocytes after treating aGVHD with ECP, 11 we found no differences in the numbers of bacterial and fungal episodes between our two groups. The median leukocyte, PMN and lymphocyte counts 3, 6, 12 and 18 months after the transplant were similar in our two groups (data not shown). In our experience, ECP seems to be effective in containing viral reactivation, enabling us to reduce the IS therapy without any worsening of the aGVHD signs and with a return to a normal viral status. The efficacy of ECP in controlling viral reactivation probably relies on its immunomodulatory effect. To the best of our knowledge, this might be a new indication for ECP.
Moreover, any concern that the immunomodulatory effect of ECP might reduce the effect of GVL was not substantiated in our small series. In fact, three relapses were recorded in the ECP group and five in the GR group. Children who underwent ECP also had a 73% CR in terms of the signs of aGVHD as opposed to a 56% CR rate in the GR group; on the other hand, the cumulative incidence of ECP for treatment of aGVHD in children E Calore et al cGVHD a year after UBMT was similar in the two groups. There were no significant differences in the TRM rate at 100 and 180 days, meaning that the early introduction of ECP was well tolerated by our pediatric patients. Moreover, a better trend in the ECP group than in the GR group was demonstrated by the 2-year rates of OS (85 vs 57%), PFS (87 vs 67%) and EFS (87 vs 63%). In short, ECP was well tolerated without any significant side effects. Our data would suggest that ECP could improve the survival of patients given UBMT. In the near future, a randomized study should be conducted on a larger group of patients to clarify this issue.
